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Abstract
Background: The farnesoid-x-receptor (FXR) is a bile acid sensor expressed in the liver and gastrointestinal tract. Despite
FXR ligands are under investigation for treatment of cholestasis, a biochemical condition occurring in a number of liver
diseases for which available therapies are poorly effective, mice harboring a disrupted FXR are protected against liver injury
caused by bile acid overload in rodent models of cholestasis. Theonellasterol is a 4-methylene-24-ethylsteroid isolated from
the marine sponge Theonella swinhoei. Here, we have characterized the activity of this theonellasterol on FXR-regulated
genes and biological functions.
Principal Findings: Interrogation of HepG2 cells, a human hepatocyte cell line, by microarray analysis and transactivation
assay shows that theonellasterol is a selective FXR antagonist, devoid of any agonistic or antagonistic activity on a number of
human nuclear receptors including the vitamin D receptor, PPARs, PXR, LXRs, progesterone, estrogen, glucorticoid and
thyroid receptors, among others. Exposure of HepG2 cells to theonellasterol antagonizes the effect of natural and synthetic
FXR agonists on FXR-regulated genes, including SHP, OSTa, BSEP and MRP4. A proof-of-concept study carried out to
investigate whether FXR antagonism rescues mice from liver injury caused by the ligation of the common bile duct, a model
of obstructive cholestasis, demonstrated that theonellasterol attenuates injury caused by bile duct ligation as measured by
assessing serum alanine aminostrasferase levels and extent of liver necrosis at histopathology. Analysis of genes involved in
bile acid uptake and excretion by hepatocytes revealed that theonellasterol increases the liver expression of MRP4, a
basolateral transporter that is negatively regulated by FXR. Administering bile duct ligated mice with an FXR agonist failed
to rescue from liver injury and downregulated the expression of MRP4.
Conclusions: FXR antagonism in vivo results in a positive modulation of MRP4 expression in the liver and is a feasible
strategy to target obstructive cholestasis.
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Introduction
Cholestasis is a liver disorder that occurs primarily in the
context of genetic mutation of basolateral or apical membrane
transporters in hepatocytes. Cholestasis represents the main
biochemical feature of primary biliary cirrhosis [1,2] (PBC) and
sclerosing cholangitis (PSC), two immune-mediated disorders
characterized by progressive bile duct destruction for which
medical therapy is still poorly effective and investigations are
ongoing to identify novel therapeutic approaches [1,2]. In addition
to PSC and PBC, an obstructive form of cholestasis occurs in
patients suffering from biliary stones or biliary and pancreatic
tumors [1]. Theoretically, because PBC and PSC are character-
ized by bile duct destruction, therapy should be aimed at
activating bile acid secretion from the basolateral membrane of
hepatocytes, while stimulation of bile acid secretion from the
apical membrane is likely to worsens liver injury due to the
obstruction of bile flow [3]. FXR is a bile acid sensor that regulates
bile acid synthesis and excretion. While activation of FXR favours
bile acid detoxification by hepatocytes and FXR ligands have been
proposed in the treatment of PBC patients [1], results from models
of obstructive cholestasis in FXR
2/2 mice have shown that FXR
gene ablation protects against liver injury caused by ligation of
common bile duct (BDL) [3]. Molecular decoding of the BDL
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30443model has lead to the demonstration that FXR functions as a
negative regulator of multidrug resistance-associated protein
(MRP)-4, a gene mediating basolateral secretion of bile acids.
Thus, while FXR
2/2 mice adapt to bile duct obstruction by an
<20 fold induction in the expression of MRP-4 mRNA, these
changes are not reproduced in wild type mice [3]. Because
induction of MRP-4 represents an adaptive response to bile duct
obstruction and protects the liver from accumulation of toxic bile
acids during cholestasis by facilitating their efflux into blood for
ultimate renal excretion, and MRP-4-knockout mice are sensitised
to liver injury induced by BDL [4], regulation of this basolateral
transporter exerts an essential role in orchestrating the adaptive
changes under conditions of impaired bile flow due canalicular
obstruction/destruction [2,5–7]. In vitro characterization of
interaction of FXR with MRP-4 has lead to the demonstration
that FXR functions as a braking signals for MRP-4 induction
caused by activation of Constitutive Androstane Receptor (CAR)
[2,5–7]. Gene promoter analysis of human MRP-4 promoter has
revealed the presence of a CAR responsive element embedded
within an FXR responsive element, an everted repeat (ER)-8,
known to mediate repression of FXR target genes [5]. Thus, it
appears that FXR competes with CAR for binding to this
overlapping binding site and FXR ligation of ER-8 displaces CAR
from the MRP-4 promoter abrogating MRP-4 induction caused
by CAR activators [2,5]. In aggregate, these data suggest that
FXR activation in obstructive cholestasis might worsen liver injury
by hijacking a protective mechanism regulated by CAR, i.e
induction of MRP-4 [2,6–8]. While these data strongly advocate
the utility of an FXR antagonist in the treatment of obstructive
cholestasis, this concept has remained unproved because the lack
of a selective FXR antagonist [2].
The observation that <40% of modern pharmaceuticals are
derived from biological sources [8–10], highlights the incredible
biomedical potential represented by the chemical analysis of
natural organisms [9,10]. As the results of enzymatic reactions,
natural products have an intrinsic capacity to recognize and bind
macromolecules, perturb their activity, and modulate biological
processes. Besides their potential use as pharmaceutical drugs,
natural products have and will continue to play critical roles as
biological probes, essential component of today’s research arsenal
and useful to dissect complex biological processes and ultimately,
to identify novel therapeutic targets. Among natural sources,
marine environment, with its vast pool of plants, animal and
micro-organisms, represents a greater promise to provide original
molecules for treatment of human diseases [9,10]. Sponges of the
genus Theonella have attracted the interest from the scientific
community for the impressive variety of bioactive secondary
metabolites with unusual structures and powerful biological effects
[7]. Representative compounds include non-ribosomal peptides
exemplified by the antifungal theonellamides, a new class of sterol-
binding molecules that induce membrane damage and activate
Rho1-mediated 1,3bD-glucan synthesis [11] and complex poly-
ketides such as the actin-bounding macrolide swinholide A [12]. In
addition, sponges of Theonella genus are distinctive in producing
biosynthetically unique sterols [7]. Decodification of these non
conventional steroids has allowed the identification of 24-
ethylsterols endowed with potent activity towards mammalian
nuclear receptors including the FXR and pregnane-X-receptor
(PXR) [7,13]. Theonellasterol is a 4-methylene-24-ethylsteroid that
has been proposed as a taxonomic marker for the Theonella sponge
phenotypes [14]. Structurally theonellasterol contains a relatively
rare 8(14) double bond and a biosynthetically unusual 4-methylene
functionality. This unusual functional group has been proposed to
biogenetically arise from a shunt in the oxidative demethylation of
the 4-methyl series, through the dehydration of the primary
alcohol formed in the first oxidation of the methyl group [14]. The
biological function of these 4-methylenesteroids is unknown.
However, their relative abundance in the apolar extract of
Theonella swinhoei as well as their ability to fit in the ligand binding
domain of FXR and PXR [7,14], emphasize a plausible role as
putative ligands for ancestral sponge nuclear receptor(s).
In the present study, we report the discovery that theonellasterol,a
4-methylenesteroids isolated from the Theonella swinhoei sponge, is a
highly selective FXR antagonist. Of interest, despite theonellasterol
was known since long time (14), its effect on nuclear receptors has
never been tested. Using this agent we have designed a proof-of-
concept study to investigate whether pharmacological antagonism
of FXR holds potential in protecting against liver injury in
obstructive cholestasis [2,5].
Results
Isolation of theonellasterol from Theonella swinhoei
The initial processing of the Theonella swinhoei (coll. No. R3170)
was conducted according to procedures described elsewhere [13].
The n-hexane extract from a solvent partitioning Kupchan
procedure was cromatographed by silica gel and the fraction
eluted with CH2Cl2:MeOH 99:1 was further purified by reverse
phase HPLC to afford 40.5 mg of theonellasterol (Figure 1) as a
colourless amorphous solid ([a]D
25+20.4 c 1 MeOH). The identity
of theonellasterol was secured by comparison of its NMR and MS
spectrum (Table S1 and Figure S1) with those previously reported
[14]. The purity was established major than 95% by HPLC trace
(Figure S2).
Docking Studies
The flexible nature of FXR side chains suggests that its ligand
binding domain (LBD) may have considerable ability to
accommodate differently shaped ligands changing its conforma-
tion in response to ligand binding [15]. In order to rationalize the
binding mode of theonellasterol on FXR receptor, we have
therefore performed docking calculations (by Autodock 4.2
software [16]) on several FXR structures co-crystallized with
different compounds [17–20] with the aim to predict the position
of the LBD in complex with theonellasterol. As reported, the
activation of the FXR by the sterol molecules is, among the others,
regulated by the interaction between the OH at C-3 of steroid
skeleton and the amino acids of the catalytic triad (namely Tyr in
Helix 7, His in Helix 10/11 and Trp in Helix 12) [20]. In all the
three dimensional models (Figure 1B) theonellasterol interacts with
the catalytic triad generating a hydrogen bonds with Tyr358 and
365 in the Helix 7 for the pdbs 1OSV [20] and 1OSH [17]
respectively, and with His447 for the pdbs 3DCT [18], 3BEJ [15],
3RUU [19], and His444 for 1OSV [20] (Helix 10/11). On the
other hand, only in the three dimensional models with 3DCT [18],
3RUU [19], and 1OSV [20] the marine sterol establishes
hydrophobic interactions with Helix 12 and in particular with
the Trp469 (3DCT [18], 3RUU [19]) or Trp466 (1OSV [20])
(Figure 1B). Considering also the additional interactions with the
LBD, we have chosen the complex with the 1OSV [20] for our
analysis because theonellasterol and 6-ECDCA show similar
chemical features with respect to the other molecules co-
crystallized with the FXR structures. On this basis, in addition
to the two hydrogen bonds between theonellasterol with Tyr358
(Helix 7) and His444 (Helix 10/11) reported above, the trans
junction between A/B rings and its peculiar unsaturation between
C-8 and C-14 causes a different spatial arrangement with respect
to the semi-synthetic agonist 6-ECDCA [20] and the natural
FXR Antagonism in Cholestasis
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the hydrophobic contact with Met362, Phe326, Phe333 and
Tyr366. On the other hand, theonellasterol’s steroid skeleton
interacts with Leu345 and Trp466 in the same manner that
guggulsterone and 6-ECDCA respectively, and with Ala288,
Leu284, and Met447; while its alkylic chains is in close contacts
with Arg328 and His291, and with Ile332 (Figure 1C) as reported
for 6-ECDCA and guggulsterone respectively. Furthermore,
theonellasterol maintains the same hydrophobic interactions of
6-ECDCA and guggulsterone with His444, Ile349, Met287,
Met325, Ser329, Tyr358 in the LBD. In conclusion, even if
theonellasterol shows a relatively simple skeleton in comparison to
the 4-methylene steroids previously described by us [13], docking
results suggest that the different pattern of hydrophobic interac-
tions established with FXR are sufficient to support its competition
with 6-ECDCA in occupying the FXR binding site [5,13,20–23].
Theonellasterol is an FXR antagonist and reverses the
effect of CDCA on the expression of canonical FXR target
genes
We have then investigated whether theonellasterol directly
transactivates or inhibits FXR transactivation caused by CDCA,
a canonical FXR ligand. For these purposes we used HepG2 cells,
an hepatocarcinoma cell line transfected with FXR, RXR, b-
galactosidase expression vectors (pSG5FXR; pSG5RXR and
pCMV-bgal) and with a p(hsp27)TKLUC reporter vector
containing the promoter of the FXR target gene heat shock
protein 27 (hsp27) cloned upstream to the Luciferase gene.
Twenty-four hour post-transfection, cells were challenged with
CDCA, 10 mmol/l, theonellasterol,1 0mmol/l, or with the combi-
nation of the two (i.e. CDCA, 10 mmol/l, and theonellasterol,
50 mmol/l) for 18 h. As shown in Figure 2A and B, theonellasterol
exerted no agonistic activity on the receptor but caused a robust
attenuation of its transactivation induced by CDCA (n=4;
P,0.05 versus CDCA). Confirming its antagonistic activity on
CDCA, exposure of HepG2 cells to 50 mM theonellasterol effectively
stabilized the nuclear corepressor NCoR at its binding site in the
promoter of OSTa, a well characterized FXR-regulated gene.
Thus, as illustrated in Figure 2C, the ChIP analysis demonstrates
that while exposure to CDCA, 10 mM, released NCoR from the
OSTa promoter, co-treating cells challenged with CDCA with the
theonellasterol, 50 mM, abrogated this pattern (n=3; P,0.05 versed
CDCA alone).
Because these data suggest that the theonellasterol was endowed
with an FXR antagonistic activity, we have then tested its effects
Figure 1. Theonellasterol from Theonella swinhoei. (A) Chemical structure of theonellasterol isolated from Theonella swinhoei. (B)
Superimposition of the different docking poses of theonellasterol in the rat FXR (theonellasterol and 1OSV [20] yellow), and human FXRs
(theonellasterol and 3BEJ [15] orange; theonellasterol and 1OSH [17] pink; theonellasterol and 3DCT [18] purple; theonellasterol and 3RUU [19] light
blue). (C) Superimposition of theonellasterol (yellow) with 6-ECDCA (sky blue), and Z (pink)/ E (light pink) gugglusterone in the binding pocket of FXR
(1OSV). Amino acids interacting with theonellasterol (yellow) are depicted in green, amino acids interacting with 6-ECDCA and theonellasterol are
depicted in sky blue, amino acids interacting with Z/E gugglusterone and theonellasterol are depicted light pink, amino acids interacting with 6-
ECDCA and Z/E gugglusterone in red, and amino acids interacting with all molecules are depicted in blue.
doi:10.1371/journal.pone.0030443.g001
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cultures of mouse hepatocytes. In this experimental setting,
theonellasterol reversed the effect of CDCA on the expression of
canonical FXR target genes [23]: OSTa, BSEP, and SHP
(Figure 3A–C; n=4; P,0.05 versus CDCA alone). Interestingly,
the antagonistic activity of theonellasterol extended also to MRP-4
(Figure 3D) [2–5]. Because the regulatory activity of theonellasterol
on MRP-4 holds promise for potential therapeutic use of this
steroid in obstructive cholestasis, we have examined in a further
detail the molecular mechanisms involved in this effect. More
specifically, we have asked whether the antagonistic activity of
theonellasterol on MRP-4 expression induced by CDCA was
promoter specific. For this purpose a ChIP assay was carried by
immune-precipitating nuclear extracts from HepG2 cells left
untreated or primed with CDCA alone or with the combination of
CDCA plus theonellasterol with an anti-FXR antibody. As shown in
Figure 3E, results of Real-Time PCRs demonstrated that while in
basal conditions, FXR is not constitutively bound to the MRP-4
promoter, but is recruited on the promoter following activation
with CDCA. Recruitment of FXR to the MRP-4 promoter in the
presence of CDCA was robustly attenuated by co-incubating the
cells with the theonellasterol (n=4; P,0.05 versus CDCA alone). All
together these results indicate that theonellasterol exerts its
antagonistic activity by reducing the binding of FXR on the
MRP-4 promoter, thus preventing its down-regulation caused by
CDCA (Figures 3D and E).
Theonellasterol is a selective FXR antagonist
To further investigate the specificity of the above described
interactions, we have tested whether theonellasterol interacts with
other nuclear receptors including PXR, PPARc, VDR and GR
(i.e.receptors that are targeted by guggulsterone [21–23]). For this
purpose we used fusions of the LBD of PPARc, VDR and GR
with a GAL4-DNA binding domain cloned into an expression
vector (pSG5). Transactivation experiments were carried out using
a reporter vector containing five repeats of the GAL4 responsive
element cloned upstream the luciferase gene (p(UAS)5x-TK-Luc).
To investigate the effect of theonellasterol on PXR, HepG2 cells were
Figure 2. Theonellasterol is an FXR antagonist. Luciferase reporter assay performed in HepG2 transiently transfected with pSG5-PXR, pSG5-RXR,
pCMV-bgal, pCYP3A4promoter-TKLuc vectors and stimulated 18 h with (A) 10 mM of CDCA or theonellasterol and (B) 10 mM of CDCA alone or in
combination with theonellasterol 50 mM. Data are the mean 6 S.E. of three experiments. *P,0.05 versus cells left untreated. #P,0.05 versus CDCA.
(C) CHiP assay of NCoR binding to the OSTa promoter. CDCA displaces NCoR from OSTa and this effect is reversed by theonellasterol. RT-PCR analysis
of proteins immune-precipitated with a control IgG are shown as control. Data are the mean 6 S.E. of three experiments. *P,0.05 versus anti IgG
immunoprecipitates. #P,0.05 CDCA versus cells left untreated; P,0.05 thenollasterol versus CDCA alone.
doi:10.1371/journal.pone.0030443.g002
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the reporter vector p(cyp3a4)TKLUC containing the PXR
response element of Cyp3A4, a canonical PXR target gene,
cloned upstream to the luciferase gene. As shown in Figure 4 A–D,
theonellasterol at the concentration of 10 mM failed to transactivate
PPARc, PXR, VDR and GR, nor it inhibited the activation of
these receptor promoted by specific ligands, i.e. rosiglitazone,
rifaximin, 1,25 dihydroxy colecalciferol and dexamethasone when
co-incubated with these selective agonists at the concentration of
50 mmol/L. To further examine the specificity of theonellasterol we
have also investigated its effects on the expression of several
nuclear receptors and co-regulatory factors by a microarray
analysis. Results of this experiment demonstrated that theonellasterol
itself had no effect on the expression of any of these regulatory
factors (not shown) and, as demonstrated in Figure 4E, the sponge
steroid caused no changes in the expression of these nuclear
receptors and regulatory factors in cells challenged with CDCA.
Effects of FXR antagonism on liver injury induced by BDL
in mice
Because these data illustrate that theonellasterol is a selective FXR-
antagonist, we have designed a proof-of-concept study to ascertain
whether this compound was effective in attenuating liver injury
caused by BDL in mice, a model of obstructive cholestasis that is
attenuated by FXR gene ablation [3]. For this purpose BDL mice
were administered the theonellasterol, 10 mg/kg, or an FXR agonist,
6-ECDCA, 30 mg/kg, for 3 days. As shown in Figure 5A and B, 3
days after BDL the size of the common bile duct increased ,10
fold (Figure 5A and B, arrows) in comparison to sham operated
animals, and while this effect was exacerbated by administering
mice with 6-ECDCA, it was attenuated by the theonellasterol,
suggesting a direct role for FXR in activation of hepatocyte’s
apical bile acid output in this setting. Changes in the common bile
duct size caused by BDL were not explained by any reduction in
the severity of bile duct obstruction, since the serum concentra-
tions of alkaline phosphatase (Alk. Phosp.), a marker of bile duct
obstruction were unchanged by theonellasterol administration, but
slightly increased by 6-ECDCA (Figure 5C). The serum
concentrations of total bile acids increased dramatically under
condition of BDL, and these changes were partially attenuated by
theonellasterol but not by the FXR agonist ( Figure 5D and E) .
Quantitative analysis of taurine (T)-conjugated bile acids
(Figure 5E) and unconjugated bile acids (Figure S4) by liquid
chromatography-mass spectrometry demonstrated that BDL
caused a marked increase in serum concentrations of T-CA) and
T-bmuricolic acid (T-bMCA). Pharmacological interventions on
BDL mice had minor impact on serum bile acid concentrations/
composition, thought that administering mice with 6-ECDCA
resulted in a significant accumulation of its T-ECDCA in the
blood (Figure 5E).
Figure 3. Theonellasterol reverses the effect of CDCA on the expression of canonical FXR target genes. Relative mRNA expression of (A)
OSTa, (B) BSEP, (C) SHP and (D) MRP4 in HepG2 cells treated with 10 mM CDCA alone or with the combination of CDCA plus theonellasterol 50 mM. (E)
CHiP assay performed in HepG2 cells not stimulated or primed with CDCA, 10 mM, alone or in combination with theonellasterol,5 0 mM.
Theonellasterol antagonizes the recruitment of FXR on the MRP4 promoter. Data are the mean 6 S.E. of three experiments. *P,0.05 versus cells left
untreated. #P,0.05 versus CDCA alone.
doi:10.1371/journal.pone.0030443.g003
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trations. Serum ALT values were markedly increased in BDL
mice, but significantly reduced by theonellasterol, while the
opposite was observed in animals exposed to 6-ECDCA
(Figure 6A; n=6; P,0.05 BDL versus sham operated and
theonellasterol versus BDL alone). Changes in AST levels were
consistent with the histopathology analysis. BDL causes hepato-
cyte’s death that is secondary to intrahepatic bile acid overload.
These necrotic areas are confluent foci of hepatocyte feathery
degeneration due to bile acid cytotoxicity. The extent of these
necrotic foci in the liver was assessed by conventional H&E
staining and quantitated using digital image analysis. Histopath-
ological examination of liver specimens demonstrated numerous
necrotic foci in untreated BDL mice. This pattern was attenuated
by theonellasterol treatment as also confirmed by histometric analysis
of the extent of liver necrosis (Figure 6B and C; P,0.05
theonellasterol versus BDL alone). The opposite was observed in
BDL mice administered 6-ECDCA.
Analysis of the expression of genes involved in bile acids
handling by the liver revealed that BDL upregulated the
expression of OSTa, MRP-4 and SHP mRNAs (Figure 7A–D;
n=4–6; P,0.05 versus BDL alone). This pattern was dramatically
changed by administering mice with theonellasterol: in fact the
marine steroid reversed the induction of OSTa and SHP caused
by BDL and caused a robust induction in MRP-4 mRNA
expression (Figure 7; n=4–6; P,0.05 versus BDL alone). The
opposite was observed in mice administered 6-ECDCA, since this
FXR agonist reduced the expression of MRP-4 in comparison to
BDL alone (n=4–6; P,0.05 versus BDL alone). Finally, while
BDL per se had no effect on BSEP mRNA, the expression of this
transporter was slightly induced by treating mice with the FXR
agonist (Figure 7; n=4–6; P,0.05 versus BDL).
Discussion
The pharmaceutical research has expanded in the last two
decades to include massive screening of marine organisms in the
search of novel drug candidates [9]. Among marine organisms,
sponges of the genus Theonella have attracted a great interest from
the scientific community for the impressive variety of bioactive
secondary metabolites with unusual structures and powerful
biological activity. In the last year extensive decoding of
Figure 4. Theonellasterol is a selective FXR antagonist. (A) (C) and (D) HepG2 cells were co-transfected with the Gal4 luciferase reporter and a
series of chimeras in which the Gal4 DNA binding domain is fused to the LBD of the indicated nuclear receptors. Cells were treated with the
appropriate agonists or specific agonists in combination with theonellasterol. (B) HepG2 cells were co-transfected with pSG5-PXR, pSG5-RXR and with
the reporter pCYP3A4promoter-TKLuc and then stimulated with rifaximin, a PXR agonist, alone or in combination with theonellasterol. Data are the
mean 6 S.E. of three experiments. *P,0.05 versus not treated cells. (E) Microarray analysis showing the relative mRNA expression of various nuclear
receptors and nuclear receptors co-activators following stimulation of HepG2 cells with CDCA, 10 mM, alone or in combination with theonellasterol,
50 mM. Data are the mean 6 S.E. of three experiments.
doi:10.1371/journal.pone.0030443.g004
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has allowed the identification of a number of marine steroids that
function as putative ligands for two nuclear receptors, FXR and
PXR [13]. Despite sponges are the simplest animal organisms,
phylogenetic analyses have revealed the existence of an ancestral
nuclear receptor that existed near the base of the Metazoa with fatty
acids as possible ancestral ligands [24]. Indeed, analysis of
sequenced genome of the demosponge Amphimedon queenslandica
has shown the presence of sequences encoding for two nuclear
receptors, named AqNR1 and AqNR2 [24]. The phylogenetic
analysis indicates that AqNR2 is orthologous to hepatocytes
nuclear factor (HNF)4, while AqNR1 is the unduplicated ortholog
of all other nuclear receptors which subsequently gave rise to all
other classes found in vertebrates. Because AqNR1 is the
precursor of all modern nuclear receptors it is likely that its ligand
binding domain accommodates a variety of structurally different
steroids, making sense to the extraordinary biodiversity of marine
steroids. The present discovery suggests that in addition to agonists
of nuclear receptors, marine sponges could generate steroids
endowed with antagonistic activity raising the question of the
functional roles these steroids might exert in the context of sponge
biology.
In the present study we report that theonellasterol is a non-
promiscuous antagonist for FXR [21–23]. This specificity was
confirmed by transactivation and microarray experiments. Indeed,
exposure of HepG2 cells to this agent, while abrogates the
transactivation of FXR caused by its natural ligand CDCA, fails to
modulate the expression of a wide array of mammalian nuclear
receptors and fails to activate PPARc, LXR, PXR and VDR in
transactivation assay. These results were confirmed by analysis of
expression of genes that are directly regulated by FXR. Thus the
theonellasterol antagonizes the effects of CDCA on expression of
OSTa, BSEP and SHP mRNAs. Because FXR regulates the
expression of these genes by direct binding to an FXR responsive
element [2,23] in their promoter, these data provide a robust
support to the notion that theonellasterol is a selective FXR
antagonist. Further confirmation to this view was obtained by
the analysis of the effect that theonellasterol exerts on the expression
of MRP-4. We have previously demonstrated that FXR binds to
an overlapping site in the MRP-4 promoter thus causing the
Figure 5. FXR agonism and antagonism lead to development of different patterns of liver injury in response to BDL. (A) Common bile
duct dilation, 3 days after BDL, is worsened by 6-ECDCA and attenuated by theonellasterol. Data are mean 6 SE of 6 mice per group. *P,0.05 versus
sham operated. ** Theonellasterol versus BDL. (B) Representative macroscopic features of common bile duct (white arrows) in 3-day BDL mice
administered theonellasterol and 6-ECDCA . (C) BDL increases serum levels of alkaline phosphatase, a marker of bile duct obstruction. Serum levels of
alkaline phosphatase were not changed by administering BDL mice with theonellasterol, while were slightly increased by 6-ECDCA. Data are the mean
6 S.E. of 6 mice per group. *P,0.05 versus sham operated. (D) Serum concentration of total bile acids. Data are the mean 6 S.E. of 6 mice per group.
*P,0.05 versus sham operated. (E) Quantitative analysis of tauro-conjugated bile acids in BDL animals. BDL increases serum concentrations of T-CA,
T-MCA and T-CDCA while secondary bile acids were almost undetected. Challenging BDL mice with 6-ECDCA increases serum levels of T-6-ECDCA.
Data are the mean 6 S.E. of 4 mice per group. *P,0.05 versus sham operated.
doi:10.1371/journal.pone.0030443.g005
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PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e30443Figure 6. BDL causes liver cell injury and theonellasterol attenuates liver necrosis. (A and B) Liver necrosis was robustly attenuated by
theonellasterol as confirmed by assessment of ALT and histopathology analysis. Data are the mean 6 S.E. of 6 mice per group. *P,0.05 versus sham.
**P,0.05 versus BDL. #P,0.05 versus BDL plus theonellasterol. (C) Representative liver histology from an individual mice per group. Liver sections
were stained with H&E, original magnification 106.
doi:10.1371/journal.pone.0030443.g006
Figure 7. Theonellasterol alters the liver expression of genes involved in bile acid metabolism in BDL mice. (A) Real-Time PCR analysis of
OSTa, (B) BSEP, (C) SHP and (D) MRP4. Data are the mean 6 S.E. of 4 mice per group. *P,0.05 versus sham. **P,0.05 versus BDL. #P,0.05 versus
BDL plus theonellasterol.
doi:10.1371/journal.pone.0030443.g007
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gene is under the negative control of nuclear corepressor NCoR,
binding of CAR to its consensus element displaces NCoR from the
MRP-4 promoter, while FXR causes the reverse [2,5]. Because
these data predict that exposure to an FXR agonist would reverse
the negative effects of FXR on MRP-4 in obstructive cholestasis,
we have examined whether theonellasterol attenuates binding of
FXR to the MRP-4 promoter in the presence of CDCA. Indeed,
the results of this experiment, shown in Figure 3E, demonstrate
that the counter-regulatory effect of CDCA on MRP-4 gene
expression is robustly reverted by theonellasterol. Because hijacking
of a CAR regulated mechanism by FXR agonists, represses MRP-
4 gene expression and contributes to bile acid-mediated liver
injury in cholestasis, its reversal by an FXR antagonist might hold
utility in treatment of these disorders [2].
Theonellasterol is significantly different from another natural FXR
antagonist, guggulsterone [21]. Indeed, while this agent was
originally reported to act as a FXR antagonist, further studies have
shown that it functions as a ligand for multiple nuclear receptors
[21,25–28], including PXR, the GR, the androgen and mineral
corticoid and progesterone receptors. Taking into consideration
that agonism of guggulsterone for these receptors takes place at
concentrations that are 20–125 lower than that required for FXR
antagonism, it is now widely accepted that agonism to these
nuclear receptors, rather than FXR antagonism, explains the
pharmacological effects of this plant steroid [23,25–28].
In the last decade, FXR has emerged as an important
therapeutic target in the treatment of liver disorders [1,2,7,23].
Among other conditions, FXR agonists have been proposed as
potential treatment for cholestatic liver disorders, i.e. a spectrum
of hepatobiliary diseases of diverse etiologies that are character-
ized by impaired hepatocellular secretion of bile, resulting in
accumulation of bile acids, bilirubin, and cholesterol in
hepatocytes [1,2]. Hepatic defence against bile acid overload
involves the activation of a complex network of metabolic
pathways leading to the repression of bile acid uptake at the
hepatic basolateral membrane of hepatocytes, inhibition of de novo
synthesis of these end product of cholesterol as well as induction
of alternative basolateral bile acid transporters [2]. A number of
genes encoding for basolateral and apical transporters undergo
adaptive changes in cholestasis. These changes are orchestrated
by modulation by a network of transcription factors including the
hepatocyte nuclear factors (HNF1, 3, 4), FXR, PXR, CAR , the
liver receptor homologue-1 (LRH-1), SHP and the glucocorticoid
receptor [1,2,23,29]. The functional relevance of these regulatory
elements in orchestrating adaptive responses has been highlighted
by various knockout models. Thus, mice lacking PXR or CAR
are more susceptible to bile acid induced liver injury than their
wild-type littermates [6,25,29,30]. In contrast, FXR gene
ablation leads to protection against liver injury induced by
BDL [3]. This protection is the result of lower serum bile acid
concentrations and altered expression of hepatic transporters,
including BSEP, MDR-1 and MDR-2 and MRP-4 [3]. Of
interest, in comparison to wild type mice, FXR
2/2 mice adapt to
bile duct ligation by a marked up-regulation of MRP-4 [3].
Despite these observations predict that the use of an FXR
antagonist should be protective in the context of obstructive
cholestasis, the testing of this hypothesis has been precluded by
the lack of a selective FXR antagonist. The discovery that
theonellasterol is a selective FXR antagonist has allowed us to carry
on a proof-of-concept study in BDL mice. The results of this
study demonstrated that in vivo administration of theonellasterol
effectively reduced intrahepatic bile duct pressure, as assessed by
measuring the size of common bile duct, and reduced the extent
of liver injury, as assessed by AST plasma levels and liver
histopathology, in BDL mice. Further on, analysis of expression
of MRP-4 in the liver of BDL mice, confirmed that pharmaco-
logical antagonism to FXR has the potential to increase MRP-4
gene expression while the opposite was observed in mice
administered with a potent FXR agonist.
Present results obtained by administering mice with a FXR
agonist are partially consistent with previous observations made in
the BDL model in rats. Indeed, we have previously shown that
long term administration of 6-ECDCA worsened the severity of
cholestasis as assessed by measuring alkaline phosphatase and
cGT [31]. In contrast, short term administration of GW4064, a
non steroidal FXR agonist, has been reported to attenuate liver
injury in BDL rats [32]. While the different chemical structure of
these ligands might provide an explanation for these findings, the
role of FXR agonism in obstructive cholestasis still await
confirmation [1,7].
In summary, we have identified a marine steroid that acts as a
selective FXR antagonist. Using this agent we have designed a
proof-of-concept study in BDL mice whose results provide
evidence that pharmacological antagonism for FXR holds
potential in the treatment of obstructive cholestasis. Present data
might have a translational readout. Indeed, beside biliary stones
and tumors, obstructive cholestasis due to inflammation and loss of
intra-hepatic bile ducts, is the key feature of advanced, stages III
and IV, PBC and PSC. This study paves the way to the
development of FXR antagonists for treatment of obstructive
cholestasis.
Materials and Methods
Sponge material and isolation of theonellasterol
Theonella swinhoei (order Lithistida, family Theonellidae) was
collected on the barrier reef of Vangunu Island, Solomon Islands,
in July 2004. Authorization to collection and exportation of sponge
samples was released by Fisheries Department of Solomon Islands
Government to IRD (Institut de Recherche pour le De `veloppe-
ment, Polynesian Research Center on Island Biodiversity, BP529,
98713 Papeete, Tahiti, French Polynesia) in the frame of a
research project entitled: ‘‘Coral Reef Initiative in The South
Pacific’’ (CRISP) ‘Biodiversite ´ et substances marines actives volet
Mole ´cules actives soutenu par l’Agence Franc ¸aise pour le
De ´veloppement’’, authorization IRD–AFDCZZ3012-02U. The
sponge lyophilized material was kindly provided by Dr. Cecile
Debitus, IRD. The sponge is not on the endangered and protected
species list (CITES list, www.cites.org) and no specific permits
were required for the described field studies.
The sample was frozen immediately after collection and
lyophilized to yield 600 g (dry mass) of R3170. Taxonomic
identification was performed by Dr John Hooper of Queensland
Museum, Brisbane, Australia, where specimens are deposited
under the accession number G3122662.
The lyophilized material (600 g) was extracted with methanol
(362.7 l) at room temperature and the methanolic extract, taken
to dryness, was subjected to a modified Kupchan’s partitioning
procedure as follows. The methanol extract was dissolved in a
mixture of MeOH/H2O containing 10% H2O and partitioned
against n-hexane (19.7 g). The water content (% v/v) of the
MeOH extract was adjusted to 30% and partitioned against
CHCl3 (17.8 g). The aqueous phase was concentrated to remove
MeOH and then extracted with n-BuOH (10 g).
The hexane extract was chromatographed by silica gel MPLC
using a solvent gradient system from CH2Cl2 to CHCl2:MeOH
1:1.
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purified by HPLC on a Nucleodur 100-5 C18 (5 mm; 10 mm
i.d.6250 mm) with MeOH:H2O (998:2) as eluent (flow rate 5 ml/
min) to give 40.5 mg of theonellasterol (tR=19.6 min) (Figure S2).
Identity of theonellasterol was established by comparison of its
RM (Table S1 and Figure S1) and mass data (Figure S2) with those
previously reported [14].
6-ECDCA was synthesized by Dr. Angela Zampella by a
modification of previously published methods [8] and as described
previously [7]. Identity of the compound was assessed according its
RM and mass data (Figure S3) with those previously published [7].
The taurine conjugated derivative of 6-ECDA (T-ECDCA) was
synthesized according to methods reported in the supporting
information to this paper (Scheme S1) and its identity confirmed
by RM and mass analysis (Figure S5).
Computational Details
We performed the molecular docking calculations by Autodock
4.2 software [16] on quad-core IntelH XeonH 3.4 GHz, using a
grid box size of 94696668, with spacing of 0.375 A ˚ between the
grid points, and centered at 20.689 (x), 39.478 (y), 10.921 (z),
covering the active site of the FXRs [15–20]. To achieve a
representative conformational space during the docking studies
and for taking into account the variable number of active torsions,
10 calculations consisting of 256 runs were performed, obtaining
2560 structures for the sterol 1. The Lamarckian genetic algorithm
(LGA) was employed for docking calculations, choosing an initial
population of 600 randomly placed individuals. The maximum
number of energy evaluations and of generations was set up to
5610
6 and to 6610
6 respectively. Results differing by less than
3.5 A ˚ in positional root-mean-square deviation (RMSD) were
clustered together and represented by the most favorable free
energy of binding. Illustrations of the 3D models were generated
the Python software [33].
Cell culture, transfection, plasmids and Luciferase assays
HepG2 cells (ATCC-LCG collections, Milan Italy) were
cultured at 37uC in Minimum Essential Medium with Earl’s salts
containing 10% fetal bovine serum (FBS), 1% L-glutamine and
1% penicillin/streptomycin as described previously [31]. The
transfection experiments were performed using Fugene HD
(Roche) according to manufactured specifications. HepG2 cells
were plated in a 6-well plate at 5610
5 cells/well. For FXR
mediated transactivation, cells were transfected with 100 ng
pSG5-FXR, 100 ng pSG5-RXR, 200 ng pCMV-bgalactosidase
and with 500 ng of the reporter vector p(hsp27)-TK-LUC
containing the FXR response element IR1 cloned from the
promoter of heat shock protein 27 (hsp27). At 48 h post-
transfection, cells were stimulated 18 h with 10 mM CDCA, with
10 mM theonellasterol or with the combination CDCA (10 mM)
plus theonellasterol (50 mM).
To investigate the theonellasterol specificity, HepG2 cells were
transiently transfected with 500 ng reporter vector p(UAS)5XTK-
Luc, 200 ng pCMV-bgalactosidase and with a series of vectors
containing the ligand binding domain of various nuclear receptors
(PPARc, VDR and GR) cloned upstream of the GAL4-DNA
binding domain (i.e. pSG5-PPARcLBD-GAL4DBD, pSG5-
VDRLBD-GAL4DBD and pSG5-GRLBD-GAL4DBD). 48 h
post-transfection, cells were stimulated 18 h with the appropriate
nuclear receptor agonist or with the agonist plus theonellasterol
(50 mM). To investigate the PXR mediated transactivation,
HepG2 cells were transfected with 100 ng pSG5-PXR, 100 ng
pSG5-RXR, 200 ng pCMV-galactosidase and with 500 ng of the
reporter vector containing the PXR target gene promoter
(CYP3A4 gene promoter) cloned upstream of the luciferase gene
(pCYP3A4promoter-TKLuc). At 48 h post-transfection, cells were
stimulated 18 h with 10 mM rifaximin, with theonellasterol
(10 mM) or with the combination of rifaximin (10 mM) and
theonellasterol (50 mM).
After treatments, cells were lysed in 100 ml diluted reporter lysis
buffer (Promega) and 10 ml cellular lysate was assayed for
luciferase activity using the Luciferase Assay System (Promega).
Luminescence was measured using an automated luminometer.
Luciferase activities were normalized for transfection efficiencies
by dividing the relative light units by b-galactosidase activity
expressed from cells cotransfected with pCMV-bgal.
Real-Time PCR
Total RNA was isolated from HepG2 using the TRIzol reagent
according to the manufacturer’s specifications (Invitrogen). One
mg RNA was purified of the genomic DNA by DNase I treatment
(Invitrogen) and random reverse-transcribed with Superscript II
(Invitrogen) in 20 ml reaction volume. Fifty ng template was added
to the PCR mixture (final volume 25 ml) containing the following
reagents: 0.2 mM of each primer and 12.5 mlo f2 6SYBR Green
qPCR master mix (Invitrogen). All reactions were performed in
triplicate and the thermal cycling conditions were: 2 min at 95uC,
followed by 40 cycles of 95uC for 20 sec, 55uC for 20 sec and
72uC for 30 sec in iCycler iQ instrument (Biorad). The relative
mRNA expression was calculated and expressed as 2
2(DDCt).
Primers used for qRT-PCR were: GAPDH: gaaggtgaaggtcggagt
and catgggtggaatcatattggaa; MRP4: ggcgaattgttagctgtggt and cag-
ggctgctgagacacata; BSEP: gggccattgtacgagatcctaa and tgcaccgt-
cttttcactttctg; OSTa: tgttgggccctttccaatac and ggctcccatgttctgctcac;
SHP: gctgtctggagtccttctgg and ccaatgatagggcgaaagaagag.
Chromatin Immunoprecipitation
10610
6 serum starved HepG2 cells were left untreated or
stimulated with CDCA (10 mM) or with the combination CDCA
(10 mM) plus theonellasterol (50 mM) for 1 h. After treatments cells
were cross-linked with 1% formaldehyde 10 min at room
temperature and then the reaction terminated by the addition of
glycine to a final concentration of 125 mM. Cells were washed in
ice-cold PBS and lysed with 500 ml ChIP lysis buffer (1% SDS,
10 mM EDTA, and 50 mM Tris-HCl, pH 8) containing 10 mM
PMSF and protease inhibitor cocktail (Sigma), sonicated and
centrifuged at 13000 rpm 10 min at 4uC. Fifty ml of each
supernatant (Input DNA) were reverse-cross-linked by the addition
of 150 ml Elution buffer (1% SDS and 0.1 M NaHCO3) and 8 ml
NaCl 5M and by heating the mixture to 65uC for 4 h. DNA was
recovered from Input by proteinase K treatment at 65uC for 1 h
followed by phenol/chloroform (1:1) extraction, ethanol precipi-
tation and dissolved into 50 ml of molecular biology grade water.
Thus, Input DNA was spectrophotometrically quantified and
40 mg chromatin was diluted with ChIP dilution buffer (0.01%
SDS, 1% Triton-X-100,1.2 mM EDTA pH 8.0, 16.7 mM Tris-
HCl pH 8.0, 167 mM NaCl) containing protease inhibitors and
20 ml of ChIP lysis buffer equilibrated Protein A Sepharose
(Amersham Bioscience) /Salmon Sperm DNA/1% BSA. After
mixing at 4uC for 1 h, the mixtures were centrifuged at 1,000 rpm
for 1 min to obtain pre-cleared supernatants. Pre-cleared
supernatants were immunoprecipitated overnight at 4uC with
4 mg specific antibodies: anti-FXR (sc-13063 - Santa Cruz, CA) or
anti IgG (SA1-36098 Pierce) as negative control. Immunoprecip-
itates were washed sequentially with low-salt wash buffer (0.1%
SDS, 1% Triton-X-100, 2 mM EDTA pH 8.0, 20 mM Tris-HCl
pH 8.0, 150 mM NaCl) and then with high-salt wash buffer
(0.1%SDS, 1% Triton-X-100, 2 mM EDTA pH 8.0, 20 mM
FXR Antagonism in Cholestasis
PLoS ONE | www.plosone.org 10 January 2012 | Volume 7 | Issue 1 | e30443Tris-HCl pH 8.0, 500 mM NaCl). DNA was eluted by addition of
250 ml Elution Buffer and the cross-linking reactions were reversed
by heating the mixture to 65uC overnight. The DNA was
recovered from immuneprecipitated material by proteinase K
treatment at 65uC for 1 h followed by phenol/chloroform (1:1)
extraction, ethanol precipitation and dissolved into 50 mlo f
molecular biology grade water. Five microliters chromatin was
used for quantitative real-time PCR. Raw data analysis was
performed as follows: DCt was calculated versus the input DNA
concentration; DDCt was versus unstimulated cells immunopre-
cipitated with the anti-IgG antibody (experimental condition set as
1.0); the relative expression was calculated as 2
2(DDCt). The
sequences of primers used for the amplification of the MRP4
promoter were: ttcctttcccaatctaagggg and gatggatgaatgctgtcgtc.
Microarray analysis
Total RNA from HepG2 cells left untreated, stimulated with
CDCA (10 mM) or with the combination of CDCA and
theonellasterol (50 mM) was extracted with Trizol reagent
(Invitrogen) and reverse transcribed with Superscript-II reverse
transcriptase (Invitrogen) following the manual instructions.
100 ng cDNA was pipetted in each well of a 96 well PCR array
plate (Human Nuclear Receptors and Coregulators RT
2 Profiler
TM
PCR Array - http://www.sabiosciences.com/rt_pcr_product/
HTML/PAHS-056A.html - Superarray Bioscience, Frederick,
MD, USA) and amplified following the manual instructions. Genes
selected for PCR analysis encode several classes of nuclear
receptors and co-regulators of transcription, including co-activa-
tors and co-repressors. PCR analysis was carried out with the on-
line software RT
2 Profiler PCR Array Data Analysis (http://
pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php).
Bile Duct Ligation
CD1 mice, 27–30 grams, (Harlan Nossan, Italy) were housed
under controlled temperatures (22uC) and photoperiods (12:12-
hour light/dark cycle), allowed unrestricted access to standard
mouse chow and tap water and allowed to acclimate to these
conditions for at least 5 days before inclusion in an experiment.
Protocols were approved by the University of Perugia Animal Care
Committee according to the Italian guideline for care and use of
laboratory animals. The ID for this project is #98/2010-B. The
authorization was released to Prof. Stefano Fiorucci, as a principal
investigator, on May 19, 2010. On the day of surgery, mice were
anesthetized with isoflurane and aseptically subjected to ligation of
the common bile duct. Sham operations were performed by gently
touching the common bile duct with forceps. Animals (n=6 per
group) were sacrificed by exsanguination under anesthesia 3 after
BDL or sham operation. The drugs was administered intraperito-
neally (25 mg/kg) for 3 days starting to the end of chirurgical
procedure. The sham and BDL group received vehicle (100 mlo f
physiologic solution containing 10% DMSO and 30% ethanol).
The latest day the drugs were administered 4 h before the sacrifice.
Mortality and the frequency of complications was less than 30%. At
the time of sacrifice, blood samples were collected for determination
of aspartate aminotransferase (AST) as a measure of liver injury and
the diameter of bile duct measured by computer caliper.
Assessment of Liver Histology
Consecutive sections of liver (4 mm thick) from paraffin-
embedded liver were stained with hematoxylin and eosin. The
extension of necrosis was quantified using a computerized image
analysis system (ImageJ Acquisition System). Images were
acquired with a BX60 microscope (Olympus Co., Rome, Italy)
and digitalized using a C14 camera (Diagnostic Instruments Inc.,
Sterling Heights, MI) with a resolution of 131561033 pixels. The
extension of necrosis in blinded specimens was measured at a
video screen display magnification and expressed as a percentage
(the ratio of damaged area per total analyzed field surface). The
average of the percentage taken from 15 random fields was used to
generate a single data for each liver.
Bile acids determination
The stock solutions of the individual tauro-conjugated bile acids
at a concentration of 1 mg/mL were prepared separately in
methanol. All the stock solutions were stored at 220uC.
Calibration standards were prepared by combining appropriate
volumes of each bile acid stock solution and methanol. The
calibration range was from 1 to 10000 nM of each bile acid in the
final solution.
Mice serum sample aliquots of 100 mL were deproteinized with
1 mL of cold acetonitrile with 5% of NH4OH vortexing for 1 min
[34–35]. After centrifugation at 16000 g for 10 min, the clear
supernatant was transferred to a new vial, snap frozen and
lyophilized. The sample was then re-dissolved in methanol–water
(2:1, v/v), centrifuged and transferred into an auto-sampler vial. A
bile acids extraction yield of 95% has been measured using bile
acids standards addition in plasma sample before and after
deproteinization procedure.
Liquid chromatography and mass spectrometry
For LC–MS/MS analysis, chromatographic separation was
carried out on the HPLC–MS system LTQ XL ThermoScientific
equipped with Accelera 600 Pump and Accelera AutoSampler
system. The mixture was separated on a Jupiter 5 m C18 column
from Phenomenex (15062.00 mm).
Compounds were separated at a flow rate of 200 ml/min using a
methanol–aqueous ammonium acetate (NH4OAc) gradient [36].
Mobile phase A (A) was 5% methanol in water containing 2 mM
NH4OAc at pH 7, mobile phase B (B) was methanol, containing
NH4OAc at 2 mM. The gradient started at 30% B and increased
to 100% B in 20 min, kept at 100% B for 5 min then decreased to
30% B in 1 min and kept at 30% B for 10 min. ESI was
performed in negative ion mode, the ion source temperature was
set at 280uC. The tune page parameters were automatically
optimized injecting taurocholic acid at 1 mM as standard. The
MS/MS detection was operated in MRM mode using a collision
energy of 20 (arbitrary units), the observed transitions were:
Tauromuricholic acid (T-MCA) at 13.5 min MRM of 514.28
ThR514.28 Th, taurocholic acid (T-CA) at 16.6 min MRM of
514.28 ThR514.28 Th, taurochenodeoxycholic acid (T-CDCA)
at 18.5 min MRM of 498.29 ThR498.29 Th, taurodeoxycholic
acid (T-DCA) at 18.9 min MRM of 498.29 ThR498.29 Th and
tauro-6-ethylchenodeoxycholic acid (T-6-ECDCA) at 20.7 min
MRM of 526.29 ThR526.29 Th [32].
Supporting Information
Scheme S1 Synthesis pathway of Tauro-6-ECDCA.
(DOC)
Figure S1 NMR spectra and ITMS spectrum for theo-
nellasterol.
(DOC)
Figure S2 HPLC trace for theonellasterol.
(DOC)
Figure S3 NMR spectra and ITMS spectrum for 6-
ECDCA.
(DOC)
FXR Antagonism in Cholestasis
PLoS ONE | www.plosone.org 11 January 2012 | Volume 7 | Issue 1 | e30443Figure S4 Free bile acid concentration in BDL animals.
(PPT)
Figure S5 NMR spectra and ITMS spectrum for tauro-
6-ECDCA.
(DOC)
Table S1 Tabulated NMR data for theonellasterol.
(DOC)
Acknowledgments
We thank the Solomon Islands government for collection permits, the
Fisheries Department, R. Sulu (University of the South Pacific in Honiara)
for their help and assistance, and Dr John Hooper for the identification of
the sponges.
Author Contributions
Conceived and designed the experiments: SF AZ. Performed the
experiments: BR AM Cd’A SC VS MGC MCM. Analyzed the data: BR
AM MVd’A AZ GB SF. Contributed reagents/materials/analysis tools:
MVd’A VS AZ GB MGC. Wrote the paper: SF AM BR AZ GB MCM.
References
1. Fiorucci S, Baldelli F (2009) Farnesoid X receptor agonists in biliary tract
disease. Curr Opin Gastroenterol 25: 252–259.
2. Jonker JW, Liddle C, Downes M (2011) FXR and PXR: potential therapeutic
targets in cholestasis. J Steroid Biochem Mol Biol. doi:10.1016/j.jsbmb.
2011.06.012.
3. Stedman C, Liddle C, Coulter S, Sonoda J, Alvarez JG, et al. (2006) Benefit of
farnesoid X receptor inhibition in obstructive cholestasis. Proc Natl Acad Sci
USA 103(30): 11323–11328.
4. Mennone A, Soroka CJ, Cai SY, Harry K, Adachi M, et al. (2006) Mrp4
2/2
mice have an impaired cytoprotective response in obstructive cholestasis.
Hepatology 43: 1013–1021.
5. Renga B, Migliorati M, Mencarelli A, Cipriani S, D’Amore C, et al. (2011)
Farnesoid X receptor suppresses constitutive androstane receptor activity at the
multidrug resistance protein-4 promoter. Biochim Biophys Acta 3: 157–165.
6. Stedman CA, Liddle C, Coulter SA, Sonoda J, Alvarez JG, et al. (2005) Nuclear
receptors constitutive androstane receptor and pregnane X receptor ameliorate
cholestatic liver injury. Proc Natl Acad Sci USA 102: 2063–2068.
7. Sepe V, Ummarino R, D’Auria MV, Chini MG, Bifulco G, et al. (2011)
Conicasterol E, a small heterodimer partner sparing farnesoid-X-receptor
modulator endowed with a pregnane-X-receptor agonistic activity, from the
marine sponge Theonella swinhoei. J Med Chem;Nov 29. [Epub ahead of
print].
8. Fiorucci S, Cipriani S, Mencarelli A, Baldelli F, Bifulco G, Zampella A (2011)
Farnesoid X Receptor Agonist for the Treatment of Liver and Metabolic
Disorders: Focus on 6-ethyl-CDCA. Mini Rev Med Chem 11: 753–762.
9. Li JWH, Vederas JC (2009) Drug discovery and natural products: end of an era
or an endless frontier? Science 325: 161–165.
10. Carlson EE (2010) Natural products as chemical probes. ACS Chem Biol 5:
639–653.
11. Nishimura S, Arita Y, Honda M, Iwamoto K, Matsuyama A, et al. (2010)
Marine antifungal theonellamides target 3beta -hydroxysterol to activate Rho1
signaling. Nat Chem Biol 6: 519–526.
12. Kobayashi M, Tanaka J, Katori T, Kitagawa I (1989) Structure of swinholide A,
a potent cytotoxic macrolide from the Okinawan marine sponge Theonella
swinhoei. Tetrahedron Lett 30: 2963–2966.
13. De Marino S, Ummarino R, D’Auria MV, Chini MG, Bifulco G, et al. (2011)
Theonellasterols and conicasterols from Theonella swinhoei. Novel marine natural
ligands for human nuclear receptors. J Med Chem 54: 3065–3075.
14. Kho E, Imagawa DK, Rohmer M, Kashman Y, Djerassi C (1981) Sterols in
marine invertebrates. 22. Isolation and structure elucidation of conicasterol and
theonellasterol, two new 4-methylene sterols from the Red Sea sponges Theonella
conica and Theonella swinhoei. J Org Chem 46: 1836–1839.
15. Soisson SM, Parthasarathy G, Adams AD, Sahoo S, Sitlani A, et al. (2008)
Identification of a potent synthetic FXR agonist with an unexpected mode of
binding and activation. Proc Natl Acad Sci U S A 105: 5337–5342.
16. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, et al. (2009)
AutoDock4 and AutoDockTools4: automated docking with selective receptor
flexibility. J Comput Chem 30: 2785–2791.
17. Downes M, Verdecia MA, Roecker AJ, Hughes R, Hogenesch JB, et al. (2003) A
chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR.
Mol Cell 11: 1079–1092.
18. Akwabi-Ameyaw A, Bass JY, Caldwell RD, Caravella JA, Chen L, et al. (2008)
Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic
acid-based analogs of GW 4064. Bioorg Med Chem Lett 18: 4339–4343.
19. Akwabi-Ameyaw A, Caravella JA, Chen L, Creech KL, Deaton DN, et al.
(2011) Conformationally constrained farnesoid X receptor (FXR) agonists:
alternative replacements of the stilbene. Bioorg Med Chem Lett 21: 6154–6160.
20. Mi LZ, Devarakonda S, Harp JM, Han Q, Pellicciari R, et al. (2003) Structural
basis for bile acid binding and activation of the nuclear receptor FXR. Mol Cell
11: 1093–1100.
21. Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, et al. (2002) A
natural product that lowers cholesterol as an antagonist ligand for FXR. Science
31: 1703–1706.
22. Meyer U, Costantino G, Macchiarulo A, Pellicciari R (2005) Is antagonism of
E/Z-guggulsterone at the farnesoid X receptor mediated by a noncanonical
binding site? A molecular modeling study. J Med Chem 48: 6948–6955.
23. Fiorucci S, Mencarelli A, Palladino G, Cipriani S (2009) Bile-acid-activated
receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose
disorders. Trends Pharmacol Sci 30: 570–80.
24. Bridgham JT, Eick GN, Larroux C, Deshpande K, Harms MJ, et al. (2010)
Protein evolution by molecular tinkering: diversification of the nuclear receptor
superfamily from a ligand-dependent ancestor. PLoS Biol 8(10): pii e1000497.
25. Wu J, Xia C, Meier J, Li S, Hu X, Lala DS (2002) The hypolipidemic natural
product guggulsterone acts as an antagonist of the bile acid receptor. Mol
Endocrinol 16: 1590–1597.
26. Owsley E, Chiang JY (2003) Guggulsterone antagonizes farnesoid X receptor
induction of bile salt export pump but activates pregnane X receptor to inhibit
cholesterol 7alpha-hydroxylase gene. Biochem Biophys Res Commun 304:
191–195.
27. Brobst DE, Ding X, Creech KL, Goodwin B, Kelley B, Staudinger JL (2004)
Guggulsterone activates multiple nuclear receptors and induces CYP3A gene
expression through the pregnane X receptor. J Pharmacol Exp Ther 310(2):
528–35.
28. Burris TP, Montrose C, Houck KA, Osborne HE, Bocchinfuso WP, et al. (2005)
The hypolipidemic natural product guggulsterone is a promiscuous steroid
receptor ligand. Mol Pharmacol 67: 948–954.
29. Teng S, Piquette-Miller M (2007) Hepatoprotective role of PXR activation and
MRP3 in cholic acid-induced cholestasis. Br J Pharmacol 151: 367–76.
30. Beilke LD, Aleksunes LM, Holland RD, Besselsen DG, Beger RD, et al. (2009)
Constitutive androstane receptor-mediated changes in bile acid composition
contributes to hepatoprotection from lithocholic acid-induced liver injury in
mice. Drug Metab Dispos 37: 1035–45.
31. Fiorucci S, Antonelli E, Rizzo G, Renga B, Mencarelli A, et al. (2004) The
nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and
protects against liver fibrosis. Gastroenterology 127: 1497–512.
32. Liu Y, Binz J, Numerick MJ, Dennis S, Luo B, et al. (2003) Hepatoprotection by
the farnesoid X receptor agonist GW4064 in rat models of intra- and
extrahepatic cholestasis. J Clin Invest 112: 1678–1687.
33. Sanner MF (1999) Python: A Programming Language for Software Integration
and Development. J Mol Graphics Modell 17: 57–61.
34. Lian Y, Suya L, Meng W, Yong S, Min D (2007) High-performance liquid
chromatography–tandem mass spectrometry for the analysis of bile acid profiles
in serum of women with intrahepatic cholestasis of pregnancy. J Chromatogr B
860: 10–17.
35. Huang J, Bathena SPR, Csanaky IL, Alnouti Y (2011) Simultaneous
characterization of bile acids and their sulfate metabolites in mouse liver,
plasma, bile and urine using LC-MS-MS. J Pharm Biomed Anal 55: 1111–1119.
36. Bobeldijk I, Hekman M, de Vries-van derWeij J, Couliera L, Ramakera R, et al.
(2008) Quantitative profiling of bile acids in biofluids and tissues based on
accurate mass high resolution LC-FT-MS: Compound class targeting in a
metabolomics workflow. J Chromatogr B 871: 306–313.
FXR Antagonism in Cholestasis
PLoS ONE | www.plosone.org 12 January 2012 | Volume 7 | Issue 1 | e30443